AstraZeneca: Corona vaccine exceed one billion dollars

Follow - up - INA

The British company AstraZeneca, announced that the sales of the vaccine Corona reached $ 1.17 billion in the first half of the year with accelerating global immunization programs.

The sales increased more than three times to reach $894 million in the three months to June, after it was $275 million in the three months to March, the company said in a statement.

AstraZeneca delivered 319 million doses in the first half of the year, including $572 million in sales in Europe and $455 million in emerging markets.

This vaccine is one of the world's leading vaccines and was vital in the UK's rapid immunization drive that enabled the British economy to fully return this month.
AstraZeneca issued its results a day after the American pharmaceutical company Pfizer raised its forecast for annual revenues and profits due to increased demand for the competing anti-Coronavirus vaccine, which the group created in cooperation with the German Biontech laboratory.

AstraZeneca CEO Pascal Soriot said, "We have made great progress with the vaccine against the Corona virus that we have developed."

"To date, AstraZeneca and its partners have delivered 1 billion doses to more than 170 countries," he added.
Sorio led the way to make AstraZeneca one of the first pharmaceutical companies in the world to produce a vaccine against the virus.
The development of the vaccine, in cooperation with scientists at Oxford University, and their decision to make it available at cost without making a profit, made the Anglo-Swedish company a household name.
Because of this decision, AstraZeneca's performance is slim compared to that of Pfizer, which expects sales of its anti-virus vaccine this year to be worth $33.5 billion.
AstraZeneca's vaccine has faced safety doubts and its use has been suspended in some European countries due to reports of rare blood clots.

The World Health Organization and the European Medicines Agency declared that the benefits outweigh the risks.
AstraZeneca added Thursday that the group's net profit rose 40 percent to $2.1 billion in the first half of the year.
Total revenue rose nearly a quarter to $15.5 billion.
Excluding profits from the coronavirus vaccine, the company's total revenue rose 14% to about $14.4 billion.
"AstraZeneca achieved another period of strong growth thanks to its performance in all regions and all epidemics," Sorio said.
"As a result, we made further progress in profits, supported continued launches, and continued our investment in research and development," he added.